Zhitong Finance App News, and Platinum Pharmaceutical-B (02142.HK) announced that revenue for the six months ending June 30, 2026 is expected to be between approximately US$120 million (equivalent to approximately HK$941 million) to approximately US$125 million (equivalent to approximately HK$980 million), while revenue for the six months ended June 30, 2025 is approximately US$101 million. Profit is expected to range from approximately US$62 million (equivalent to approximately HK$486 million) to approximately US$67 million (equivalent to approximately HK$525 million) for the six months ended June 30, 2026. The total adjusted profit is expected to range from US$70 million (equivalent to approximately HK$549 million) to US$75 million (equivalent to approximately HK$588 million).

Zhitong Finance App News, and Platinum Pharmaceutical-B (02142.HK) announced that revenue for the six months ending June 30, 2026 is expected to be between approximately US$120 million (equivalent to approximately HK$941 million) to approximately US$125 million (equivalent to approximately HK$980 million), while revenue for the six months ended June 30, 2025 is approximately US$101 million. Profit is expected to range from approximately US$62 million (equivalent to approximately HK$486 million) to approximately US$67 million (equivalent to approximately HK$525 million) for the six months ended June 30, 2026. The total adjusted profit is expected to range from US$70 million (equivalent to approximately HK$549 million) to US$75 million (equivalent to approximately HK$588 million).